Stefanie Flückiger, TOLREMO Therapeutics

What happens when the science you built a company on becomes the science you desperately wish could save someone close?

How do you transform as a leader as your company evolves?

And why should you actively seek out friction when building your company?

Today I’m joined by Stephanie Flueckiger, co-founder and CEO of TOLREMO Therapeutics based in Basel, Switzerland. TOLREMO is developing small molecules to reprogram cancer for longer patient benefit.

As usual, we’ll talk a bit more about the science at the end of the episode.

About LifeScience ORG

It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

Chapters

0:00 — From Science to Purpose

1:17 — A Founder's Call to Action

5:52 — Tragedy at the Start

9:27 — Evolving as a Leader

14:41 — Leading Calmly Under Pressure

17:54 — The Swiss and European Ecosystem

21:30 — Communicating Across Cultures

24:42 — The Science of Drug Resistance

29:49 — Embracing Friction